PB-EEA-5g-OSK2M2L1-PGK-Puro
(Plasmid
#102909)
-
PurposePiggyBac transposon system construct for expression of 10 gRNAs targeting OCT4, MYC, KLF4, SOX2 and LIN28A promoters and 5 gRNAs targeting EEA-motif. Includes PGK-puro selection cassette.
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 102909 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonePB-GG-PGK-puro
-
Vector typeMammalian Expression, CRISPR
-
Selectable markersPuromycin
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameEEA-5g-OSK2M2L1-gRNAs-PGK-Puro
-
gRNA/shRNA sequence15 gRNAs, see full sequence
-
SpeciesH. sapiens (human)
-
Entrez GenePOU5F1 (a.k.a. OCT3, OCT4, OTF-3, OTF3, OTF4, Oct-3, Oct-4, Oct3/4)
-
Entrez GeneSOX2 (a.k.a. ANOP3, MCOPS3)
-
Entrez GeneKLF4 (a.k.a. EZF, GKLF)
-
Entrez GeneMYC (a.k.a. MRTL, MYCC, bHLHe39, c-Myc)
-
Entrez GeneLIN28A (a.k.a. CSDD1, LIN-28, LIN28, ZCCHC1, lin-28A)
- Promoter U6
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site unknown (unknown if destroyed)
- 3′ cloning site unknown (unknown if destroyed)
- 5′ sequencing primer unknown (Common Sequencing Primers)
Resource Information
-
Supplemental Documents
-
Article Citing this Plasmid
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
PB-EEA-5g-OSK2M2L1-PGK-Puro was a gift from Timo Otonkoski (Addgene plasmid # 102909 ; http://n2t.net/addgene:102909 ; RRID:Addgene_102909) -
For your References section:
Human pluripotent reprogramming with CRISPR activators. Weltner J, Balboa D, Katayama S, Bespalov M, Krjutskov K, Jouhilahti EM, Trokovic R, Kere J, Otonkoski T. Nat Commun. 2018 Jul 6;9(1):2643. doi: 10.1038/s41467-018-05067-x. 10.1038/s41467-018-05067-x PubMed 29980666